Featured Videos

ORLANDO, FL USA (UroToday.com) - Dr. Lucas Regis presented an institutional series on whether free serum testosterone (FT) or total testosterone (TT) can be a surrogate marker for the clinical benefit of androgen suppression in prostate cancer patients. The mean follow up for their study was 107 months (range: 22-304 months). A total of 36 patients (49.3%) developed castration resistance (CR), 15 patients (20.5%) developed metastatic spread, and 6 patients (9.2%) died of disease. From 73 patients who were on LHRH agonist for at least 12 months, they obtained TT (chemiluminescent assay-lower sensitivity 10 nd/dL) and FT (analogue ligand radioimmunoassay-lower sensitivity 0.05 pg/mL). In order to establish the castration level of FT with clinical impact, survival analysis using 50, 32 and 20 ng/dL for TT, and 1.7, 1.1 and 0.7 pg/mL for FT was performed.

auaOn multivariable analysis, FT (OR=4.33, p <0.001) and Gleason score (OR=2.73, p < 0.005) were the two independent predictors of survival, independent of CR. Dr. Regis reported that any TT threshold demonstrated significant differences for survival. In comparison, FT of 1.1 pg/mL was the lower threshold and showed significant differences in survival free of CR. The active form of testosterone (FT) represents 2% of TT while 40% is bound to SHBG and 58% to albumin.

In this study, authors show that in comparison to TT, FT is a better surrogate marker of CR in patients who are receiving LHRH agonist.

Presented by Lucas Regis at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Barcelona, Spain

Written by Reza Mehrazin, MD, medical writer for UroToday.com



Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.